Leuprorelin medicinal composition injection type hypodermic implantation agent

A technology of leuprolide and implants, applied in the directions of drug combination, drug delivery, hydrocarbon compound active ingredients, etc., can solve problems such as body damage, poor patient compliance, etc.
CN105535933AInactive Publication Date: 2016-05-04SHENZHEN JYMED TECH
3 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHENZHEN JYMED TECH
Publication Date
2016-05-04
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a leuprorelin medicinal composition injection type hypodermic implantation agent. The leuprorelin medicinal composition injection type hypodermic implantation agent is characterized in that medicine active ingredients are leuprorelin, plant extract and hormone or resistance hormone active medicine cooperating with leuprorelin; in addition, an implantation agent is injected subcutaneously in a liquid mode, under the effect of the body temperature, the solution is changed into gel, and then the effect of controlled release of multiple sex hormone dependent diseases is exerted. Through the implantation agent prepared through the method, on the one hand, the use amount is reduced while the medicine effect is kept, toxic and side effects are reduced, and medicine use safety and compliance are improved; on the other hand, the medicine is slowly released in the body, and the long-acting effect of treating the sex hormone dependent diseases is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medicine preparation, in particular to a leuprolide pharmaceutical composition injection-type subcutaneous implant and a preparation method thereof. Background technique

[0002] Leuprorelin (Leuprorelin / Leuprolideacetate, LA), as a gonadotropin-releasing hormone antagonist, is a polypeptide drug that can stimulate the pituitary gland to secrete gonadotropins and induce reproductive organs to produce steroids. Long-term large-scale use will inhibit the secretion of gonadotropins from the pituitary gland and the production of testicular or ovarian steroids, and can treat or alleviate a variety of sex hormone-dependent diseases such as prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

[0003] Long-term large-scale medication of LA has hidden dangers of drug accumulation and many side effects, such as allergic-like symptoms, bone pain, feminization of male breasts, cardiovascular dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More